LIBX-A403
Based on 1 Customer Validation
LIBX-A403 is a potent, selective and reversible ACSL4 inhibitor with a human IC50 of 0.049 μM and a Kd of 0.29 μM. LIBX-A403 binds in the ACSL4 fatty acid pocket in an ATP-dependent manner. LIBX-A403 prevents cell ferroptosis. LIBX-A403 can be used for the researches of cancer and parkinson's disease.
For research use only. We do not sell to patients.
- Purity: 99.23%
- Formula: C21H17NO5
- Molecular Weight:363.36
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Ferroptosis Compound Library
HY-L051
-
Anti-Parkinson's Disease Compound Library
HY-L085
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Highly Selective Inhibitors Library
HY-L158
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Biological Activity
|
ACSL4 |
LIBX-A403 inhibits hACSL4 with an IC50 of 0.049 μM and a Kd of 0.29 μM and no activity against ACSL3 at concentrations up to 50 μM[1].
LIBX-A403 (18 h pretreatment) potently inhibits RSL3 (HY-100218A)-induced ferroptosis in MDA-MB-231 cells with an EC50 of 172 nM and no cytotoxicity up to 25 μM[1].
LIBX-A403 (10 μM; 2 h) engages with endogenous ACSL4 in MDA-MB-231 cells, as confirmed by increased thermal stability of the protein[1].
LIBX-A403 (2.5 μM; 4 h pretreatment) significantly inhibits Arachidonic acid (HY-109590) + Fe-induced ferroptosis and reduces lipid peroxidation in LUHMES dopaminergic neurons[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MDA-MB-231 human breast cancer cell
-
Concentration:10 μM
-
Incubation Time:2 h
-
Result:Increased the thermal stability of ACSL4, as evidenced by higher levels of soluble ACSL4 protein at elevated temperatures compared to DMSO-treated controls.
-
Cell Line:LUHMES human dopaminergic neuron
-
Concentration:2.5 μM
-
Incubation Time:4 h (pretreatment); 48 h (AA+Fe exposure)
-
Result:Significantly protected LUHMES cells from AA+Fe-induced ferroptosis, with a marked reduction in lipid peroxidation compared to untreated ferroptosis-induced cells.
Showed protection comparable to that achieved with ACSL4 siRNA.
Chemical Information
-
Appearance Solid
-
Molecular Weight 363.36
-
Formula C21H17NO5
-
Color Off-white to light yellow
-
SMILES
O=C(C1=C(C2=CC(/C=C/C(OC)=O)=CC=C2O1)NC(C)=O)C3=CC=CC=C3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 20 mg/mL (55.04 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.7521 mL | 13.7605 mL | 27.5209 mL | 68.8023 mL |
| 5 mM | 0.5504 mL | 2.7521 mL | 5.5042 mL | 13.7605 mL | |
| 10 mM | 0.2752 mL | 1.3760 mL | 2.7521 mL | 6.8802 mL | |
| 15 mM | 0.1835 mL | 0.9174 mL | 1.8347 mL | 4.5868 mL | |
| 20 mM | 0.1376 mL | 0.6880 mL | 1.3760 mL | 3.4401 mL | |
| 25 mM | 0.1101 mL | 0.5504 mL | 1.1008 mL | 2.7521 mL | |
| 30 mM | 0.0917 mL | 0.4587 mL | 0.9174 mL | 2.2934 mL | |
| 40 mM | 0.0688 mL | 0.3440 mL | 0.6880 mL | 1.7201 mL | |
| 50 mM | 0.0550 mL | 0.2752 mL | 0.5504 mL | 1.3760 mL |
Powered by Bioz